首页 / 院系成果 / 成果详情页

Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment 期刊论文

编号：

f6cd67dc-b007-4a5b-b377-8fe55e358abd
作者：

Li, GuoJun^[1];Yu, YiQi(喻一奇)^[2]Chen, ShaoLong(陈少隆)^[2]Fan, Ping^[3];Shao, LingYun(邵凌云)^[2]Chen, JiaZhen(陈嘉臻)^[2]Li, ChangShui^[1];Yi, Bin^[1];Chen, WeiCun^[1];Xie, ShuYuan^[1];Mao, XiaoNa^[1];Zou, HeHui^[1];Zhang, WenHong(张文宏)*^[2,4,5,6]
语种：

English
期刊：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ISSN：0066-4804 2015 年 59 卷 7 期 (4121 - 4128) ; JUL
收录：
摘要：

Nucleos(t)ide analogues rarely result in a durable off-treatment response in chronic hepatitis B infection, whereas pegylated interferon (Peg-IFN) induces a long-lasting response only in a subset of patients. We assessed the effect of sequential combination therapy with Peg-IFN-alpha 2a and entecavir in hepatitis B e antigen (HBeAg)-positive patients with prior long-term entecavir therapy and investigated the predictors of response to treatment. HBeAg-positive individuals who did not achieve HBeAg seroconversion during previous long-term entecavir therapy, receiving Peg-IFN-alpha 2a added to ongoing entecavir therapy (sequential combination [S-C] therapy; n = 81) for 48 weeks or remaining on entecavir monotherapy (n = 116), were retrospectively included. A matched pair was created at a 1: 1 ratio from each treatment group. The primary endpoint was HBeAg seroconversion at week 48. Subgroup analysis of response prediction was conducted for 81 patients with S-C therapy. More patients in the S-C therapy group achieved HBeAg seroconversion than those in the entecavir group (44% versus 6%; P < 0.0001). An HBeAg level of <200 signal-to-cutoff ratio (S/CO) at baseline was a strong predictor for higher HBeAg seroconversion than that achieved when HBeAg was >= 200 S/CO (64.2% versus 17.9%; P < 0.0001). Hepatitis B surface antigen (HBsAg) levels at baseline and the decrease in HBsAg levels predicted HBsAg loss in the S-C therapy group. The combination of baseline HBeAg of <200 S/CO and HBsAg of < 1,000 IU/ml and an HBsAg decline at week 12 of >= 0.5 log(10) IU/ml provided the highest rate of HBeAg seroconversion (92.31%) and HBsAg loss (83.3%) at week 48. Patients receiving sequential combination therapy have a higher rate of HBeAg seroconversion and are more likely to experience HBsAg clearance than do those continuing entecavir monotherapy. Sequential combination therapy can be guided by baseline HBsAg/HBeAg levels and on-treatment HBsAg dynamics.
推荐引用方式
GB/T 7714：

Li Guo-Jun,Yu Yi-Qi,Chen Shao-Long, et al. Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment [J].ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2015,59(7):4121-4128.
APA：

Li Guo-Jun,Yu Yi-Qi,Chen Shao-Long,Fan Ping,&Zhang Wen-Hong.(2015).Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,59(7):4121-4128.
MLA：

Li Guo-Jun, et al. "Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment" .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 59,7(2015):4121-4128.

浏览次数：5  下载次数：0

分享到：

浏览次数：5

下载次数：0

打印次数：0